Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription 15.09.2025 1 Am J Clin Pathol 1 Am J Surg 1 Ann Oncol 7 Ann Surg Oncol 1 BMJ 1 Breast Cancer 2 Breast Cancer (Dove Med Press) 1 Breast Cancer Res 5 Breast Cancer Res Treat 1 Breast J 3 Cancer Cell 2 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 1 Cancer Res 2 Clin Breast Cancer 1 Clin Cancer Res 5 Eur J Surg Oncol 5 Eur Radiol 1 Exp Cell Res 1 Histopathology 2 Int J Cancer 1 Int J Oncol 1 Int J Radiat Oncol Biol Phys 1 J Pathol 2 Oncogene 1 PLoS Biol 6 PLoS One 1 Radiology 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Pathol

1. LEE SE, Hsu SC, Hung TH, Ng KF, et al
   Collagenase type IV improves the quality of HER2 fluorescence in situ hybridization for breast cancers.
   Am J Clin Pathol. 2025;164:342-350.
   PubMed         Abstract available
   
   

   
   Am J Surg

2. SARFRAZ A, Khalil M, Rashid Z, Altaf A, et al
   Racial/ethnic and socioeconomic disparities in cancer mortality hotspots: A multi-state geospatial analysis.
   Am J Surg. 2025;248:116492.
   PubMed         Abstract available
   
   

   
   Ann Oncol

3. TRAPANI D, Martins-Branco D, Curigliano G, Gennari A, et al
   Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline.
   Ann Oncol. 2025 Aug 12:S0923-7534(25)00914-7. doi: 10.1016/j.annonc.2025.
   PubMed        
   
   

   
   Ann Surg Oncol

4. JENSEN S, Tvedskov T, Bechmann T, Tramm T, et al
   ASO Author Reflections: Is Axillary Lymph Node Dissection Always Justified for Residual Axillary Disease in Breast Cancer After Neoadjuvant Chemotherapy?
   Ann Surg Oncol. 2025 Sep 12. doi: 10.1245/s10434-025-18302.
   PubMed        
   
   
5. AN SJ, Spanheimer PM
   Reply to Letter to the Editor: "Reassessing Predictors of Nodal Pathologic Complete Response in Breast Cancer: Methodological Strengths and Data Gaps in the National Cancer Database Analysis," by Altundag.
   Ann Surg Oncol. 2025 Sep 10. doi: 10.1245/s10434-025-18234.
   PubMed        
   
   
6. TEKCAN SANLI DE, Sanli AN
   Comment on TAD Outcomes from the Danish Breast Cancer Group Database.
   Ann Surg Oncol. 2025 Sep 10. doi: 10.1245/s10434-025-18318.
   PubMed        
   
   
7. SHOJAEIAN F, Vasigh M, Del Calvo H, Chaves LG, et al
   Neoadjuvant Versus Adjuvant Therapy for Metaplastic Breast Cancer: Insights from the National Cancer Database-Is There a Winning Strategy?
   Ann Surg Oncol. 2025 Sep 10. doi: 10.1245/s10434-025-17937.
   PubMed         Abstract available
   
   
8. NELIS M, Chichura A, Al-Hilli Z
   ASO Author Reflections: Reevaluating Treatment Sequence in Metaplastic Breast Cancer.
   Ann Surg Oncol. 2025 Sep 9. doi: 10.1245/s10434-025-18316.
   PubMed        
   
   
9. TEKCAN SANLI DE, Sanli AN
   Preoperative Radiation Boost in Early-Stage Breast Cancer: Effect on Re-excision and Complication Rates.
   Ann Surg Oncol. 2025 Sep 6. doi: 10.1245/s10434-025-18322.
   PubMed        
   
   
10. KYEI I, Bea VJ, Gyan KK, Adjei E, et al
    Oncologic Anthropology and the African Diaspora: Twenty-Year Anniversary Report, International Center for the Study of Breast Cancer Subtypes (ICSBCS).
    Ann Surg Oncol. 2025 Sep 6. doi: 10.1245/s10434-025-17807.
    PubMed         Abstract available
    
    

    
    BMJ

11. XIA Y, Zhu Y, Ling L, Xu F, et al
    Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial.
    BMJ. 2025;390:e084290.
    PubMed         Abstract available
    
    

    
    Breast Cancer

12. YAMAGUCHI-TANAKA M, Kurihara Y, Takagi K, Sato A, et al
    C-type lectin-like domain family 2 (CLEC2D) promotes proliferation and migration of breast cancer and serves as a poor prognostic factor.
    Breast Cancer. 2025 Sep 12. doi: 10.1007/s12282-025-01777.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

13. XU X, Li X
    The Role of The Xihuang Pill in Inhibiting Triple-Negative Breast Cancer Through Immunogenic Cell Death.
    Breast Cancer (Dove Med Press). 2025;17:793-803.
    PubMed         Abstract available
    
    
14. ZHANG K, Wu S, Zhou Y, Chen H, et al
    Investigation of Thrombocytopenia Associated with Trastuzumab Emtansine Treatment in Breast Cancer: A Retrospective Study in a Chinese Population.
    Breast Cancer (Dove Med Press). 2025;17:781-791.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

15. KVIST A, Kampe A, Torngren T, Tesi B, et al
    Polygenic scores in Familial breast cancer cases with and without pathogenic variants and the risk of contralateral breast cancer.
    Breast Cancer Res. 2025;27:160.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

16. DINGER TL, Volders JH, Kuijer A, Kelder JC, et al
    Evaluating clinical response to primary endocrine therapy in elderly breast cancer patients in routine practice.
    Breast Cancer Res Treat. 2025 Sep 12. doi: 10.1007/s10549-025-07809.
    PubMed         Abstract available
    
    
17. ELIAS N, Karak FE, Damaj N, Hajj A, et al
    Effects of intermittent discontinuation cyclin-dependent kinase inhibitors on metastatic breast cancer during Lebanon's economic crisis.
    Breast Cancer Res Treat. 2025 Sep 11. doi: 10.1007/s10549-025-07794.
    PubMed         Abstract available
    
    
18. NEZIREVIC S, Anders C, Dent S, Bansal R, et al
    Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2025 Sep 11. doi: 10.1007/s10549-025-07818.
    PubMed         Abstract available
    
    
19. FIELDER AM, Kim S, Ruterbusch JJ, Martin C, et al
    Prescription and self-reported use of endocrine therapy among black hormone receptor-positive breast cancer survivors in the Detroit Research on Cancer Survivors cohort.
    Breast Cancer Res Treat. 2025 Sep 9. doi: 10.1007/s10549-025-07816.
    PubMed         Abstract available
    
    
20. TARUNO K, Den H, Takeuchi M, Inuzuka M, et al
    Clinicopathologic features and contralateral breast cancer risk in BRCA1/2 pathogenic variant carriers: a multicenter registry study of Japanese women.
    Breast Cancer Res Treat. 2025 Sep 6. doi: 10.1007/s10549-025-07815.
    PubMed         Abstract available
    
    

    
    Breast J

21. XIA K, Chen E, Hu R, Pagano I, et al
    Applicability of Oncotype DX Testing in a Diverse Breast Cancer Population in Hawaii.
    Breast J. 2025;2025:9104103.
    PubMed         Abstract available
    
    

    
    Cancer Cell

22. ZHOU YF, Ma D, Shao ZM
    TNBC's compass: Navigating prognosis with a cellular map.
    Cancer Cell. 2025;43:1598-1600.
    PubMed         Abstract available
    
    
23. HE D, Wu Q, Tian P, Liu Y, et al
    Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps.
    Cancer Cell. 2025;43:1622-1636.
    PubMed         Abstract available
    
    
24. JASSIM A, Nimmervoll BV, Terranova S, Nathan E, et al
    Gene context drift identifies drug targets to mitigate cancer treatment resistance.
    Cancer Cell. 2025;43:1608-1621.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

25. CHEN JH, Slack Tidwell RS, Kai M, Lucci A, et al
    Impact of Postpartum Diagnosis on Survival of Women with Inflammatory Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    
26. KIM EY, Shin S, Chang Y, Ryu S, et al
    Serum Ferritin and Iron-Related Biomarkers in Relation to Breast Cancer Risk by Menopausal Status: A Prospective Cohort Study.
    Cancer Epidemiol Biomarkers Prev. 2025 Sep 8. doi: 10.1158/1055-9965.EPI-25-0923
    PubMed         Abstract available
    
    

    
    Cancer Lett

27. YAZDI N, Pourjamal N, Katainen R, Vaananen J, et al
    Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates.
    Cancer Lett. 2025;630:217900.
    PubMed         Abstract available
    
    

    
    Cancer Res

28. MOLDRUP RIJ, Terp MG, Jakobsen ST, Ravnsborg T, et al
    SWI/SNF Functions as a Gatekeeper of Enhancer Chromatin Access to Control Progression of Mesenchymal Triple-Negative Breast Cancer.
    Cancer Res. 2025 Sep 10. doi: 10.1158/0008-5472.CAN-24-1660.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

29. WANG L, Wang Y, Liu C, Zhao Y, et al
    The USP8/CEP55/CHMP6 Axis Orchestrates Triple-Negative Breast Cancer Progression by Regulating Ferroptosis and Macrophage M2 Polarization.
    Clin Breast Cancer. 2025 Aug 10:S1526-8209(25)00230.
    PubMed         Abstract available
    
    
30. HU C, Liu J, Liu S, Peng P, et al
    Mendelian Randomization Study: The Impact of Gut Microbiota on Survival in HR+ Breast Cancer Patients Under Different Treatment Regimens Through the Modulation of Immune Cell Phenotypes.
    Clin Breast Cancer. 2025 Aug 5:S1526-8209(25)00221.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

31. KOLBERG HC, Schumacher J, Erber R, Braun M, et al
    Atezolizumab monotherapy window preceding combined neoadjuvant chemo- and immune therapy in triple negative breast cancer (TNBC) - the neoMono trial.
    Clin Cancer Res. 2025 Sep 11. doi: 10.1158/1078-0432.CCR-25-1288.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

32. GELDART J, Barrett E, Morad A, Harvey J, et al
    Timing matters: A comparative analysis of synchronous and metachronous mammoplasty techniques.
    Eur J Surg Oncol. 2025;51:110109.
    PubMed         Abstract available
    
    
33. DINCER B, Yukruk FA, Irkkan SC, Kaya C, et al
    Does surgical margin status truly affect local recurrence in benign and borderline phyllodes tumors of the breast?
    Eur J Surg Oncol. 2025;51:110195.
    PubMed         Abstract available
    
    
34. PERMUTT A, Patel R, Thiruchelvam PT, Leff DR, et al
    Immediate or delayed contralateral symmetrisation in therapeutic mammoplasty-A systematic review.
    Eur J Surg Oncol. 2025;51:110226.
    PubMed         Abstract available
    
    
35. JAVAID H, Marin I, Montalvan J, Healy L, et al
    Current options and future perspectives for margin assessment in breast conservation surgery.
    Eur J Surg Oncol. 2025;51:110215.
    PubMed         Abstract available
    
    
36. MICHOT A, Giraud A, Karanian M, Lae M, et al
    Radiation-associated angiosarcoma of the breast: consider chemotherapy.
    Eur J Surg Oncol. 2025;51:110202.
    PubMed         Abstract available
    
    

    
    Eur Radiol

37. ALLAJBEU I, Nanaa M, Manavaki R, Papalouka V, et al
    Improving the diagnostic performance of contrast-enhanced mammography through lesion conspicuity and enhancement quantification.
    Eur Radiol. 2025;35:6385-6397.
    PubMed         Abstract available
    
    
38. GOTO M, Le Bihan D, Sakai K, Yamada K, et al
    Reduction of biopsy rate in BI-RADS4 breast lesions: potential of an abbreviated advanced DWI protocol.
    Eur Radiol. 2025;35:6421-6432.
    PubMed         Abstract available
    
    
39. COZZI A, Di Leo G, Houssami N, Gilbert FJ, et al
    Preoperative breast MRI for invasive ductal carcinoma with or without a DCIS component at needle biopsy: influence on surgical outcomes in the MIPA study.
    Eur Radiol. 2025;35:6433-6443.
    PubMed         Abstract available
    
    
40. TENDERO R, Larroza A, Perez-Benito FJ, Perez-Cortes JC, et al
    Breast cancer risk assessment for screening: a hybrid artificial intelligence approach.
    Eur Radiol. 2025 Sep 11. doi: 10.1007/s00330-025-11980.
    PubMed         Abstract available
    
    
41. YANG P, Wang M, Mao J, Cai P, et al
    Impact of intraoperative radiotherapy vs postoperative radiotherapy on survival in early-stage breast cancer patients.
    Eur Radiol. 2025 Sep 12. doi: 10.1007/s00330-025-11879.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

42. GUGALAVATH S, Malla M, Podilapu AR, Lee JM, et al
    Silencing CD151 gene in donor triple-negative breast cancer cells attenuates exosome-driven functions of recipient cells.
    Exp Cell Res. 2025;452:114740.
    PubMed         Abstract available
    
    

    
    Histopathology

43. MAKHLOUF S, Almalki N, Sheha A, Atallah NM, et al
    Outcome prediction of oestrogen receptor-positive breast cancer based on a panel of oestrogen receptor-regulated genes.
    Histopathology. 2025 Sep 12. doi: 10.1111/his.15557.
    PubMed         Abstract available
    
    

    
    Int J Cancer

44. KAUKONEN D, Ploner A, Zeng E, Bergqvist J, et al
    Evaluating distant recurrence-free survival and location of metastasis in HER2+ breast cancer by ER status.
    Int J Cancer. 2025 Sep 6. doi: 10.1002/ijc.70135.
    PubMed         Abstract available
    
    
45. JOSHI SN, Dharpawar TS, Kulkarni SR, Chaudhari PS, et al
    Comparison of iBreastExam with clinical breast examination for early detection of breast cancer in community outreach clinics in Pune, India.
    Int J Cancer. 2025 Sep 6. doi: 10.1002/ijc.70137.
    PubMed         Abstract available
    
    

    
    Int J Oncol

46. HUANG X, Luo W, Liu W, Liu X, et al
    Progerin regulates actin cytoskeletal remodeling and inhibits EMT and metastasis in triple?negative breast cancer cells.
    Int J Oncol. 2025;67:92.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

47. WRIGHT JL, Croke J, Kirova Y, Braunstein LZ, et al
    Less Is More: Current Trials Redefining Locoregional Therapy in Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2025;123:323-327.
    PubMed        
    
    

    
    J Pathol

48. SIMPKINS C, Toska E
    Sparking malignancy: nicotine as a driver of stemness and metastasis in triple-negative breast cancer(dagger).
    J Pathol. 2025 Sep 9. doi: 10.1002/path.6475.
    PubMed         Abstract available
    
    

    
    Oncogene

49. DONG X, Dai H, Yao L, Lin Y, et al
    EMC2 promotes triple negative breast cancer growth by protecting FDFT1 from endoplasmic reticulum associated degradation to impair ferroptosis susceptibility.
    Oncogene. 2025 Sep 10. doi: 10.1038/s41388-025-03545.
    PubMed         Abstract available
    
    
50. TIAN L, Jiao X, Wang C, Li D, et al
    PPARgamma acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific binding.
    Oncogene. 2025;44:3476-3492.
    PubMed         Abstract available
    
    

    
    PLoS Biol

51. ANSARI MN, Jha SK, Khan A, Rajput K, et al
    The mTORC2 subunit RICTOR drives breast cancer progression by promoting ganglioside biosynthesis through transcriptional and epigenetic mechanisms.
    PLoS Biol. 2025;23:e3003362.
    PubMed         Abstract available
    
    

    
    PLoS One

52. RAHIMZADEH S, Bentham J, Burczynska B, Farzadfar F, et al
    Spatiotemporal disparity of breast cancer incidence in Iranian female populations at the district level from 2000 to 2021: Bayesian disease mapping.
    PLoS One. 2025;20:e0330017.
    PubMed         Abstract available
    
    
53. JIA C, Yang F
    Integrative network toxicology and molecular docking reveal 4-Nonylphenol's multifaceted mechanisms in breast cancer pathogenesis.
    PLoS One. 2025;20:e0331944.
    PubMed         Abstract available
    
    
54. BRAUN T, Huesmann S, Pfister K, Friedl TWP, et al
    The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors.
    PLoS One. 2025;20:e0331203.
    PubMed         Abstract available
    
    
55. YUN H, Noh S, Cho H, Ko EY, et al
    AI-Driven quality assurance in mammography: Enhancing quality control efficiency through automated phantom image evaluation in South Korea.
    PLoS One. 2025;20:e0330091.
    PubMed         Abstract available
    
    
56. JAFRIN S, Aziz MA, Barek MA, Reza MS, et al
    Association of missense variant DCLRE1B rs3761936 with breast and cervical cancer risk-A case-control study.
    PLoS One. 2025;20:e0331492.
    PubMed         Abstract available
    
    
57. RAMZAN R, Bukhari SA, Rasul A
    Identification of silibinin and isotretinoin as potent up-regulators of sFRP4 (Wnt antagonist): In silico prediction and in vitro validation in breast cancer.
    PLoS One. 2025;20:e0331735.
    PubMed         Abstract available
    
    

    
    Radiology

58. KO ES, Yu JH, Woo SY, Kim SW, et al
    Calcifications Affect Pathologic Complete Response and MRI Prediction after Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-positive Breast Cancer.
    Radiology. 2025;316:e250718.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

59. WANG DQ, Yan L, Wu HF, Zhong YH, et al
    Prospective cohort study to validate esophageal dose constraints and predictive models for esophagitis in patients with breast cancer undergoing hypofractionated regional nodal radiotherapy.
    Radiother Oncol. 2025;212:111120.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.